^
    over1year
    CART-TnMUC1-01: A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers (clinicaltrials.gov)
    P1, N=16, Terminated, Tmunity Therapeutics | N=112 --> 16 | Trial completion date: Oct 2036 --> Dec 2022 | Active, not recruiting --> Terminated; The sponsor finds the risk/benefit analysis unfavorable and has terminated the study.
    Enrollment change • Trial completion date • Trial termination • CAR T-Cell Therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    HER-2 negative
    |
    cyclophosphamide • fludarabine IV • Tn MUC1 CAR T-cell therapy
    over2years
    CART-TnMUC1-01: A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers (clinicaltrials.gov)
    P1, N=112, Active, not recruiting, Tmunity Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed • CAR T-Cell Therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    HER-2 negative
    |
    cyclophosphamide • fludarabine IV • Tn MUC1 CAR T-cell therapy
    over4years
    CART-TnMUC1-01: A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers (clinicaltrials.gov)
    P1, N=112, Recruiting, Tmunity Therapeutics | Active, not recruiting --> Recruiting | N=80 --> 112 | Trial completion date: Jul 2034 --> Oct 2036
    Clinical • Enrollment open • Enrollment change • Trial completion date • CAR T-Cell Therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    HER-2 negative
    |
    fludarabine IV • Tn MUC1 CAR T-cell therapy • cyclophosphamide intravenous
    over4years
    CART-TnMUC1-01: A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers (clinicaltrials.gov)
    P1, N=80, Active, not recruiting, Tmunity Therapeutics | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed • CAR T-Cell Therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    HER-2 negative
    |
    fludarabine IV • Tn MUC1 CAR T-cell therapy • cyclophosphamide intravenous